Antigen News and Research

RSS

A breakthrough molecular discovery could neutralize gluten and protect coeliac patients

A research project led by the Institute for Research in Nutrition and Food Safety (INSA) and the Faculty of Pharmacy and Food Sciences at the University of Barcelona, together with the Molecular Biology Institute of Barcelona (IBMB) of the CSIC (which stands for Consejo Superior de Investigaciones Científicas), has successfully designed and tested a gluten-degrading molecule that is a promising ally in the management of coeliac disease, an autoimmune disease whose symptoms are triggered by the consumption of gluten and other prolamins found in cereals.

14 May 2026

Turning the flu virus into a powerful tool to fight cancer

A recent Views & Comments article published in Engineering highlights advances in repurposing influenza viruses as flexible therapeutic platforms for infectious diseases and cancer, driven by progress in reverse genetics and viral vector engineering.

14 May 2026

New mRNA adjuvant dramatically boosts T-cell vaccine responses in mice

MIT engineers have developed a new way to amplify the T-cell response to mRNA vaccines - an advance that could lead to much more powerful cancer vaccines and stronger protection against infectious diseases.

13 May 2026

A century of safety: Aluminium vaccine adjuvants do not raise serious long-term health risks

A BMJ systematic review of 59 human studies found no evidence supporting causal links between aluminum-adjuvanted vaccines and serious or long-term outcomes such as autism spectrum disorder, asthma, autoimmune conditions, or other chronic illnesses. The most consistent adverse events were uncommon, local, self-limited persistent nodules or granulomas, likely reflecting delayed-type hypersensitivity.

11 May 2026

Engineered regulatory T cells offer a path toward immunosuppression-free transplants

Organ transplantation remains the cornerstone treatment for end-stage organ failure. While conventional broad-spectrum immunosuppression effectively controls acute rejection, it fails to address chronic rejection and carries long-term side effects including infection, malignancy, and metabolic disorders.

8 May 2026

Promising new Hanta virus vaccine under development by University of Bath researchers

A highly promising vaccine for Hanta virus is being developed by researchers from the University of Bath. The team is led by Professor Asel Sartbaeva, Chemistry researcher at the University and co-founder of University spinout company Ensilitech.

8 May 2026

A new combined therapy to boost the immune system against cancer

Cancer immunotherapy is built on a simple but powerful idea: the immune system can recognize and destroy cancer cells if it is properly activated. In many patients, however, this response is too weak or too slow to be effective.

7 May 2026

First European trial tests CAR T therapy in amyloidosis patients

Three patients with light chain amyloidosis have been treated with CAR T cell therapy in the first European clinical trial testing the safety and efficacy of this immunotherapy in this patient group, led by UCL and UCLH researchers.

6 May 2026

USF researchers develop AI framework to predict immune system responses

Artificial intelligence is increasingly being used to help scientists accelerate drug discovery and search for new treatments.

6 May 2026

Phase 2 human clinical trial paves way for effective hookworm vaccine

A phase 2 human clinical trial of an antigen for a parasitic infection caused by hookworms has been shown to be effective in limiting the intensity of infection, paving the way for the development of a vaccine.

5 May 2026

Photodynamic strategies enhance antibacterial performance of titanium orthopedic implants

The increasing global aging population has led to a steady rise in the demand for titanium orthopedic implants.

5 May 2026

New genomic study tracks rare blood disease in children

Aplastic anemia is a rare, life-threatening blood disorder where patients are unable to make enough blood cells due to the immune system's attack on blood stem cells. The condition can progress to myelodysplastic syndrome (MDS) and leukemia. A study led by scientists at St. Jude Children's Research Hospital, with multiple collaborating institutions, used state-of-the-art genomic techniques to profile 619 children and adults with aplastic anemia.

4 May 2026

New tools for quicker and easier Mpox diagnosis

Following the rise in monkeypox (Mpox) cases, particularly in countries where the disease had not traditionally been observed, the World Health Organization (WHO) declared a Public Health Emergency of International Concern in June 2022 and again in August 2024.

4 May 2026

How fast your face ages may predict cancer survival outcomes

The study links facial aging rates to cancer outcomes, suggesting a new prognostic tool that could personalize treatment and enhance patient survival.

1 May 2026

Food timing may shape how T cells respond to infection and therapy

Short-term nutritional state can reshape T cell metabolism, with post-meal lipid metabolism enhancing T cell metabolic capacity, cytokine production, and persistence after activation. The study identifies triglyceride-rich chylomicrons as key drivers of this effect, suggesting nutritional timing may matter for immune monitoring, vaccination research, and cell-therapy manufacturing.

30 Apr 2026

Pretargeted radioimmunotherapy shows promise for colorectal cancer treatment

A new pretargeted radioimmunotherapy (PRIT) technique has been shown to be safe and effective in eradicating tumors from a preclinical colorectal cancer model.

30 Apr 2026

Extracellular vesicles from T cells enhance tumor immune response

Activated immune cells secrete tiny capsules bearing DNA that can enter other immune and tumor cells to stimulate the body's defense systems, according to a study led by investigators at Weill Cornell Medicine.

30 Apr 2026

From killers to strategists: CAR T cells enter their multifunctional era

A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shifting toward multitargeted, safety-controlled, cytokine-secreting, and checkpoint-modulating CAR T cells, but manufacturing, regulation, and limited clinical outcome data remain key barriers.

30 Apr 2026

Single-cell sequencing reveals why some CAR-T therapies succeed while others fail

Single-cell RNA sequencing is giving researchers a clearer view of why some CAR-T cells persist, expand, kill tumors effectively, or become exhausted. The review synthesizes 44 clinical scRNA-seq studies involving 500 patients and highlights how exhaustion, memory, cytotoxicity, clonal diversity, and metabolism may shape CAR-T responses.

30 Apr 2026

Metabolic rewiring could help CAR-T cells fight solid tumors

This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells inside solid tumors. It highlights metabolic reprogramming as a promising strategy to improve CAR-T cell persistence, adaptability, and anti-tumor function.

29 Apr 2026